Equities research analysts expect that Stemline Therapeutics Inc (NASDAQ:STML) will announce earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings of ($0.66) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 25.8%. The firm is scheduled to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Stemline Therapeutics will report full-year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next year, analysts anticipate that the firm will post earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million.

Several research analysts have recently commented on the stock. BidaskClub cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 14th. Roth Capital reaffirmed a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, May 23rd. ValuEngine cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Wedbush cut shares of Stemline Therapeutics from an “outperform” rating to a “neutral” rating and set a $18.00 target price on the stock. in a report on Monday, May 13th. They noted that the move was a valuation call. Finally, Piper Jaffray Companies set a $23.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Monday, March 18th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $25.20.

In related news, COO Kenneth Hoberman sold 25,817 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total transaction of $368,408.59. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 14.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Rubric Capital Management LP acquired a new stake in Stemline Therapeutics in the first quarter valued at approximately $38,614,000. BlackRock Inc. boosted its stake in shares of Stemline Therapeutics by 30.9% in the 1st quarter. BlackRock Inc. now owns 2,703,489 shares of the biopharmaceutical company’s stock valued at $34,740,000 after purchasing an additional 638,250 shares in the last quarter. Polar Capital LLP boosted its stake in shares of Stemline Therapeutics by 12.1% in the 4th quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock valued at $21,875,000 after purchasing an additional 248,616 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Stemline Therapeutics by 3,363.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,363,968 shares of the biopharmaceutical company’s stock valued at $17,527,000 after purchasing an additional 1,324,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after purchasing an additional 18,487 shares in the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.

Shares of STML traded down $0.13 during mid-day trading on Wednesday, hitting $13.29. 296,805 shares of the company’s stock were exchanged, compared to its average volume of 631,847. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $18.15. The stock has a market capitalization of $586.25 million, a PE ratio of -4.44 and a beta of 1.25. The company has a current ratio of 5.07, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Article: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.